The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Acquisition expands Merck’s growing hematology portfolio
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Subscribe To Our Newsletter & Stay Updated
